Knowthestock.com
CEMI - Chembio Diagnostics Inc.

Sell

Weak GrowthEarnings/Profit is Negative

20%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -5.79%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -78.6%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.22
Debt Ratio is 0.57
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Chembio Diagnostics Inc. (CEMI)
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Exchange - NASDAQ CAPITAL MARKET
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO -
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.